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ABSTRACT. It has been shown that acute administration of 
interleukin-1 (IL-1 ) to rats elicits a transitory increase in plasma 
ACTH and corticosterone (B) levels. To investigate the effects 
of chronic administration of IL-1 on plasma ACTH and B levels, 
in the present study rats were equipped with Alzet osmotic 
minipumps loaded with either IL-1 (delivery rate 0.5, 2.0, or 4.0 
fig/ 24 h, ip, for 1 week) or saline. At the end of the treatment 
the rats were decapitated, the adrenals were weighed, and the in 
vitro release of 0-endorphin (0E) by the anterior pituitary and 
that of B by the adrenal gland were measured. Continuous 
administration of 2.0 and 4.0 fig IL-1/24 h resulted in a persistent 
increase in plasma ACTH and B concentrations compared to 
the levels in saline-infused rats, with peak levels on the first day 
of administration. In addition, adrenal weights of IL-1 rats were 
significantly higher than those of saline rats. The 4.0-fig IL-1/  
day in vivo treatment induced an increase in spontaneous in 
vitro secretion of (3E and B, while the in vitro responses of the
S UBSTANTIAL evidence has now accumulated that 
there is a functional relationship between the im­
mune and the (neuro)endocrine system. Interleukin-1 
(IL-1), a pleiotropic polypeptide synthesized and released 
predominantly by macrophages, acts as a primary media­
tor of the acute phase response to microbial invasion and 
physical stressors (1, 2). In addition to its role in the 
coordination of host defense mechanisms, IL-1 is thought 
to serve as a trigger for the activity of the hypothalamo- 
pituitary-adrenal (HPA) axis, which is chronically stim­
ulated under these conditions (3-5).
Evidence for this idea is primarily based on in vivo 
experiments in laboratory animals. It has been shown
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pituitary (to CRF) and the adrenal (to ACTH) of animals treated 
in vivo with IL-1 were significantly diminished. IL-1 at a dose 
of 0.5 fig failed to affect plasma ACTH and B values, adrenal 
weight, and in vitro (3E and B secretion. Chronic infusion of rats 
with 4.0 fig IL-l/day induced prolonged fever, whereas at lower 
doses of IL-1 (2.0 and 0.5 fig), temperatures were elevated only 
on the first 2 days of infusion. IL-1 at doses of 2.0 and 4.0 fig/ 
day induced suppression of body weight gain on the first 2 days 
of the treatment period compared to saline treatment. Plasma 
norepinephrine and/or epinephrine concentrations were raised 
only on day 1 of the 2.0- and 4.0-fig IL-1 experiments. Thus, the 
observed effects of IL-1 on the hypothalamo-pituitary-adrenal 
axis probably do not result merely from stress induced by the 
treatment. Taken together, our data show the potential of IL-1 
to induce a dose-dependent and long term activation of the 
pituitary-adrenal axis. (Endocrinology 130: 1153-1164, 1992)
that acute administration of IL-1 activates the HPA axis 
in mice and rats, as manifested by increased levels of 
ACTH and/or corticosterone (B) in plasma (3, 6-8). 
Whether IL-1 can directly act at the pituitary and/or 
adrenal level to release ACTH and B, respectively, is still 
controversial. Strong evidence exists that the brain is 
the primary site of action, and that IL-1, either directly 
or indirectly, acts at the level of the hypothalamus by 
stimulation of CRF release (6, 7, 9-12). In these studies 
IL-1 was administered as a single bolus injection in 
relatively high doses, and plasma levels of ACTH and/ 
or B were followed for only a few hours. IL-1 has been 
shown to induce fever (13), to inhibit food intake (14- 
16), and, in high doses, to be toxic to the animal (17). 
Little or no attention has been given in studies on the 
effects of IL-1 on the HPA axis to the question of 
whether these effects resulted from a direct action of IL- 
1 on the HPA axis or were secondary to stress effects 
induced by IL-1 administration.
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Increased levels of IL-1 and, in particular, of IL-6 and 
tumor necrosis factor have been measured in biological 
fluids of patients suffering from infection or inflamma­
tory diseases (18-20). In the present study we investi­
gated whether IL-1 is capable of mediating long term 
changes in HPA activity. To mimic the setting of chron­
ically elevated IL-1 production that is thought to occur 
during some infectious diseases, we implanted osmotic 
minipumps in rats in order to infuse low doses of 0.5,
2.0, and 4.0 fig IL-l/day continuously during a period of
1 week. ACTH and B levels were measured in blood 
samples, which were withdrawn daily by means of a 
chronic jugular cannula. In addition, we investigated the 
in vitro secretion of 0-endorphin (/3E) and B from pitui­
tary and adrenal glands of rats chronically infused with 
IL-1 or saline in vivo. To detect stress effects, particular 
attention was given to the effects of chronic administra­
tion of IL-1 on body temperature and food consumption 
and on plasma levels of the stress hormones PRL, nor­
epinephrine (NE), and epinephrine (E). In the present 
longitudinal study we show that continuous infusion of 
rats with low doses of IL-1 elicits a long term activation 
of the HPA axis, and it is evidenced that these effects of 
IL-1 are not simply secondary to stress effects induced 
by IL-1 administration.
M aterials and Methods
Test materials
R ecom binant hum an  IL-1/3 (rh IL -1/?) was kindly provided 
by Dr. D. Boraschi (Sclavo, Siena, Italy). T he  p repara tion  has 
a specific activity of 109 U /m g  protein  on D10.G4.1 cells, 
corresponding to 105 U /fig vs. the  in terim  IL-1/3 reference 
reagent 86/552. According to the  specifications of the suppliers, 
endotoxin contam ination  was negligible ( < 1.2 ng lipopolysac- 
carides/m g IL -1). rhIL-1/3 was diluted in sterile pyrogen-free 
saline.
Anim als
Male albino W istar ra ts  (Cpb:WU) were obtained from the 
local breeding facility. T hey were individually housed in P lex­
iglass cages in an  artificially lighted room (lights on a t  0700 h; 
lights off a t  1900 h). R ats  were provided commercial ra t  chow 
(R M H -T M , Hope Farm s, W oerden, T he N etherlands) and  tap  
w ater ad libitum. A t the  s ta r t  of the  experim ents ra ts  were 10 
weeks old and  weighed 200-220 g.
In  vivo experim ental procedures
To dim inish the  stress caused by the  experim ental proce­
dures, the  anim als were hand led  daily by the  experim entator, 
s ta rting  1 week before cannulation . Body weight was m easured 
daily a t 0800 h, and  food and  w ater in take was estim ated  by 
weighing the  residual food and  w ater for individual cages. Body 
tem perature  was m easured serially twice a day between 0830- 
0900 h and  between 1300-1430 h in conscious hand-held  ra ts  
by insertion of a therm al probe into the  rectum . T h e  probe was
connected to a digital tem peratu re  m onitor (Digital DT100, 
E lbatron, Kerkdriel, T he  N etherlands). T he mean daily te m ­
perature  for each ra t  was determ ined by averaging the  m orning 
and afternoon rectal tem peratures.
Blood was collected from freely moving ra ts  by m eans of a 
chronic cannula. R ats were cannula ted  according to the  m ethod 
described by Steffens (21) w ith some m inor modifications. 
Briefly, under pen tobarb ita l (60 m g/kg BW, ip; A pharm a, 
Arnhem , T he N etherlands)-a trop ine (0.125 mg/kg, im; P har- 
machemie, H aarlem , T he N etherlands) anesthesia, a Silastic 
cannula  (id, 0.5 mm; od, 0.94 mm: Dow-Corning Corp., M id­
land, MI) was inserted into the  right external jugular vein and 
passed down to the atrium . T he distal end of the  cannula  was 
tunneled  sc and  exteriorized through a stab wound in the  skin 
on the  head, where it was connected to a hooked stainless steel 
tube. T h is  assembly was anchored to the  skull w ith three  
stainless steel screws and acrylic cement. D uring cannulation, 
ra ts  were continuously exposed to a gas flow of 0 2-N 20  (each 
500 m l/m in). T he  cannula  was filled w ith a 0.9% NaCl solution 
contain ing heparin  (500 IU /m l; Organon Teknika, Oss, T he 
N etherlands) and  polyvinylpyrrolidone (1 g/ml; Merck, D arm s­
tad t, Germ any).
Seven to 9 days after cannulation , ra ts  were equipped with 
osmotic m inipum ps (1 fi\/h\ model 2001, Alzet Corp., Palo 
Alto, CA), which were loaded with rh IL -1 dissolved in sterile 
pyrogen-free physiological saline or with saline alone and  equil­
ibrated, im m ersed in saline, for 3-4  h a t  37 C according to the 
instructions of the  m anufacturer. T he  pum ps were im planted 
ip in e ther-anesthetized  anim als (1400-1600 h). T hree  separate 
experim ents, each including 14 anim als, were performed, in 
which 1 group of ra ts  (n =  7) was continuously infused a t a 
ra te  of 0.5, 2.0 , or 4.0 fig IL - l /d a y - ra t .  In each experim ent a 
control group (n =  7) receiving 0.9% pyrogen-free saline-filled 
osmotic pum ps was included. T he  indwelling cannula and  the 
osmotic pum ps were to lerated  well by the  animals, w ith no 
signs of discomfort or infection.
At the  end of the  experim ents, the  pum ps filled with IL-1 
were found to be encapsulated by a firm layer of granulation 
tissue, with deposition of collagen and  abu n d an t fibroblasts 
and  capillaries. Pum ps delivering the  higher doses of IL-1 (4.0 
and  2.0 fig IL -l/d ay )  were more encapsulated th a n  those deliv­
ering 0.5 /ig/day. Saline-loaded pum ps were no t encapsulated. 
M rosovsky et al. (22) elegantly showed th a t  encapsulation of 
the pum ps does no t block the  release of IL -1 into the  peritoneal 
cavity and  th a t  IL-1 under these circum stances rem ains bioac­
tive for a t least 1 week.
Blood sampling. Blood was collected once a day for 8 days 
s ta rting  on the  m orning before im plan ta tion  of the  pum ps (day
0 up to day 7), as described by W iersm a and  Castelijn (23) with 
some m inor modifications. Because of the circadian variation 
in horm one release, blood was w ithdraw n daily from the  an i­
mals between 1000-1200 h. Blood samples (2.0 ml) for ACTH, 
B, PR L , E, and  N E  determ inations were collected in prechilled 
tubes contain ing  dry lith ium -heparin  additive (30 U S P  U /tube; 
Vacutainer, Becton Dickinson, E tten-L eur, T he  N etherlands). 
Blood samples were gently shaken and spun for 10 min a t 1500 
X  g  (4 C). P lasm a was separated, and  red blood cells were 
resuspended in sterile physiological saline (1.5 ml) and re tu rned
/
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to each rat. For P R L  determ ination , p lasm a (80 ¿¿1) was diluted 
with 160 fi\ PBS, and  for catecholam ine determ ination , plasm a 
was stored in tubes contain ing 0.24 M E G T A  (Merck) and  0.2 
M glutathione (Sigma, St. Louis, MO). P lasm a samples were 
aliquoted and stored a t  —20 C until assayed.
In  vitro experim ental procedures
R ats were decapitated  8 days after im plan ta tion  of the  
pumps. Im m ediately after decapitation  (1000-1030 h) the  brain  
was removed, the  p itu ita ry  gland was taken  out, and the  an te ­
rior lobe (AL) was carefully separated  from the  neuro in term e­
diate lobe. T he  adrenals were removed and  placed together with 
the ALs in a tissue holder contain ing  ice-cold carbogenated 
superfusion medium.
Superfusion. After dissection, the  adrenals were freed of fat, 
weighed, cut in about 16 pieces, and  transferred  to a superfusion 
appara tus (2 adrenals of 1 an im al/cham ber). ALs were q u a r t­
ered and  also transferred  to the  appara tus  (1 A L/cham ber). 
T he  tissues were superfused continuously w ith carbogenated 
K rebs-R inger bicarbonate buffer (118 m M  NaCl, 4.85 m M  KC1, 
1.15 m M  K H 2P 0 4, 1.15 m M  M g S 04.7H20 ,  25 m M  N a H C 0 3, and 
1.25 m M  CaCl2-2H20 )  supplem ented w ith BSA (Sigma fraction 
V; 0.5%), ascorbic acid (0.1 m M ) ,  and  glucose (11.1 m M ;  super­
fusion medium). T he  flow rate  was kept co n s tan t a t  0.1 m l/ 
min using a Gilson M inipuls 3 peristaltic  pum p (Meyvis, Bergen 
Op Zoom, T he N etherlands). T he  tem pera tu re  of the  superfu­
sion cham bers and media was kept co n s tan t a t 37 C. In  all 
experim ents, the  tissues were first superfused for 45 min to 
allow the  release of /5E im m unoreactiv ity  (/3E-IR) and  B to 
reach a ra th e r  stable level. From  th en  on, fractions (15 min; 
1.5 ml) were collected in ice-chilled tubes, and  superfusion was 
continued for 165 m in w ithout fu rther experim ental m an ipu­
lations. After th is  period, the  ALs were exposed for 30 min 
(fractions 12-13) to medium contain ing  10-9 M ra t  CRF (Byk, 
Zwanenburg, T he  N etherlands), and  the  adrenals for 60 min 
(fractions 12-15) to medium contain ing  250 pg /m l A C TH  
(M RC 74/555). T hereafter, superfusion was continued for a n ­
o ther 120 (ALs) or 90 (adrenals) m in w ith the  in itial medium. 
One hundred-m icroliter aliquots of the  AL superfusate frac­
tions were taken  for direct RIA of /3E-IR, whereas the  to tal 
adrenal superfusate fractions (1.5 ml) were taken  for B de te r­
m ination.
Calculations. T he  spontaneous ra te  of release of 0E -IR  and  B 
was no t identical for the  different ALs or adrenals w ithin  the  
same experim ent. T o  compare results between the  superfusion 
chambers, the  to ta l am oun t of drug-induced /3E-IR (fractions 
12-17) or B (fractions 13-19) release was sum m ated  and  ex­
pressed as a percentage of the  calculated basal release. T he 
area under the  line linking the  m eans of the  /3E-IR or B con ten t 
of the  two fractions im m ediately preceding (/3E-IR, fractions 
10- 11; B, fractions 11- 12) and  the  first two fractions in which 
stabilization of the  release to  basal levels had  occurred (0E-IR , 
fractions 18-19; B, fractions 20-21) was taken  as basal release.
Hormone extraction and m easurem ent
A C TH . Extraction from  anterior pituitaries: T he  A C TH  con ten t 
of the  an terio r p itu ita ry  was investigated in a separate  fourth
experim ent. A nterior p itu itaries of ra ts  were rapidly dissected 
on the  seventh day of continuous infusion with 2.0 fig IL - l /d a y  
or saline. A nterior p itu itaries  were frozen in liquid nitrogen 
and stored a t  —20 C. These tissues were heated  for 10 min in
1.0 N acetic acid (1:10, w t/vol) in a boiling w ater ba th  and  
subsequently cooled on ice. T hen , the  tissues were homogenized 
by sonification and  centrifuged a t  20,000 x  g  for 20 m in a t  4 C. 
T he su perna tan ts  were evaporated to dryness, and  the  residues 
were dissolved in 1 ml PB S  containing 0.25% BSA and  0.2% 
sodium azide. Insoluble m aterial was removed by centrifuga­
tion, and the  su p ern a tan ts  were stored a t —20 C.
Extraction from  plasma: For m easurem ent of A C TH  in ra t  
plasma, 50-/A aliquots of p lasm a sample to each of which 250 
fi\ A CTH -free hum an  p lasm a (pooled from 20 healthy  volun­
teers after suppression of A C TH  secretion by dexam ethasone) 
had been added was used. A C TH  was extracted  and  concen­
tra ted  from tissue ex tracts  and  plasm a by the  addition of 25 
mg Vycor glass powder (325 mesh; Corning Glass W orks, 
Corning, NY) in 250 f±\ bidistilled water. T he  m ixture was 
inverted end over end for 30 m in a t 4 C. After centrifugation 
(2,000 X  g; 10 min; 4 C), the  su perna tan ts  were discarded. T he 
pellets were washed w ith 2 ml bidistilled w ater and  2 ml 1 N 
HC1, respectively. A C TH  was eluted from the  glass pellet by 
ro tation  (30 min a t 4 C) w ith 1 ml of a m ixture of acetone and 
bidistilled w ater (50:50, vol/vol). After centrifugation, the  ace­
tone fractions were decanted and  evaporated to dryness, and 
the residues were reconstitu ted  in 125 ¡i\ of a solution con ta in ­
ing 0.9% NaCl and 0.25% BSA (ORHD 20/ 21, Behring, M ar­
burg, Germ any), pH  3.5, a t  4 C for 60 m in to ensure m axim al 
reuptake of the  hormone. After centrifugation for 45 m in a t
30.000 x  g, a 100-yLxl aliquot was taken  from th is  solution for 
estim ation of the  A C TH  con ten t by RIA. S tan d ard  curves were 
prepared by spiking A CTH -free plasm a w ith A C TH  (M RC 74/ 
555). T he s tandard  samples were subjected to the  same ex trac­
tion procedure as the  unknow ns in order to com pensate for 
procedural losses. T he  recovery was approxim ately 70%. All 
samples were ex tracted  in triplicate.
RIA: A C T H -IR  in the  superna tan ts  was m easured by RIA, 
using a commercial A C TH  antibody (IgG Corp., N a sh ­
ville, T N ). A C T H -(l-3 9 )  was used as standard , and [125I] 
A C T H -(1-39) as tracer. T he  A C TH  RIA was perform ed as 
follows. One hundred  microliters of rabbit A C TH  antiserum  
[final dilution, 1:30,000 in A C TH  RIA buffer (phosphate buffer 
containing 13 mM ED TA , 0.02% sodium azide, 0.25% BSA 
(ORHD 20/21, Behring), 0.1% T rito n  X-100, and  250 kallikrien 
inhibitor un its  apro tonine (Bayer, Leverkusen, G erm any)/m l] 
were added to 100 ft 1 su p e rn a tan t (sample or standard). T he 
m ixture was preincubated  for 3 days a t 4 C with antiserum . 
Then, tracer (~7000 dpm /100 fd) was added, and  incubation 
was continued for ano ther day. Bound and  free A C TH  were 
separated  by a second antibody system. One hundred  microli­
ters of a separation  reagent [10% (vol/vol) sheep an tirabb it 
immunoglobulin G and  0 .01% (wt/vol) rabbit immunoglobulin 
G (Sigma)] were added to each tube and  incubated for 20 m in 
a t room tem perature . T he  antibody complex was precip itated  
by the  addition of 1 ml 7.5% polyethylene glycol 6000 (Merck). 
T he sensitivity of the  assay system was 10-15 pg/m l, and  the  
within- and  betw een-assay coefficients of variation  of the  ex­
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trac tion  and RIA procedure were 9.1% and 15.3%, respectively. 
B. P lasm a B was m easured by RIA after extraction using an 
antiserum  from our own laboratory (S-05 230676) raised in 
sheep against a B -21-hem isuccinate-BSA conjugate. T he fol­
lowing cross-reactivities (expressed as percentage on a mass 
basis) were obtained: desoxy-B, 28.6%; cortisone, 0 .2%; cortisol,
0.8%; deoxycortisol, 0.3%; testosterone, 3.8%; and progester­
one, 22.5%. To each plasm a sample (50 ¿d), 100 fi\ 0.1 N N aOH , 
100 ¡¿I B tracer [ [ l a ,2a--N-3H]B; A m ersham  In terna tional PLC, 
Amersham, Aylesbury, Buckingham shire, U nited  Kingdom;
10,000 dpm in 0 .2% ethylene glycol (M erck)/w ater (EGW)] 
and 500 jul bidistilled w ater were added. E xtraction  was carried 
out using 7.5 ml dichlorom ethane (Baker, Deventer, T he N e th ­
erlands). T he w ater phase was discarded, and  the dichloro­
m ethane phase was evaporated. T he residue was dissolved in 2 
ml 0.2% EGW , and the concentration  of B in the eluate was 
m easured by RIA. Briefly, aliquots of 100, 200, or 300 fil eluate 
were transferred  to tes t tubes, and the volume was made up to 
300 fi\ with 0.2% EG W  and mixed with 200 fi\ of an antiserum  
dilution (final dilution, 1:100,000) and 100 /¿I B tracer (10,000 
dpm /tube). A ntiserum  and tracer were diluted in 0.05 M borate 
buffer (pH 8.0) containing 0.1% hum an 7 -globulin (Beriglobin
S, Behring, M arburg, Germany). Aliquots of 300 fi\ eluate were 
taken  for recovery. A m ounts of 0-5,000 fm ol/tube B (Stera- 
loids, Inc., W ilton, N H) diluted in 0 .2% EG W  were used for 
obtaining a s tandard  curve. After incubation overnight a t 4 C, 
the suspension was mixed with 150 ¡A dextran-coated  charcoal 
suspension and left a t 4 C for 5 min. After centrifugation, the 
superna tan ts  were decanted into counting vials, and 4 ml 
Aqualuma (Lumac LSC, Olen, Belgium) was used as counting 
solution for radioactivity m easurem ents. T he sensitivity of the 
assay was 25-45 fm ol/tube. T he within- and between-assay 
coefficients of variation were 10.0% and 16.7%, respectively.
B produced by adrenal glands in vitro was m easured fluoro- 
metrically, as described by Goverde et al. (24).
PRL. P lasm a P R L  levels were m easured directly by RIA, using 
reagents [purified ra t P R L  (AFP-10505B) for iodination; rabbit 
an tira t  P R L  antiserum  (AFP-131581580), and ra t P R L  refer­
ence preparation  (AFP-4459B)] obtained from the N ID D K  
through the  courtesy of Dr. Raiti of the  N ational H orm one and 
P itu ita ry  Program , U niversity  of M aryland School of Medicine. 
T he RIA was perform ed in essence as described by W iersm a 
(25). T he sensitivity of the  assay was 160 pg/m l, and the within- 
assay coefficient of variation was 4.4%. All necessary com par­
isons between te s t and control anim als were made w ithin one 
assay run. D ata  are expressed as picograms of P R L  per ml 
plasma.
Catecholamines. P lasm a catecholam ines (E and NE) were de­
term ined  by using H PLC , followed by fluorescence detection, 
as described in detail by van der H oorn et al. (26). C atechol­
amines were concentrated  from plasm a by liquid-liquid ex trac­
tion and derivatized with the fluorescent agent 1,2-diphenyle- 
thylenediam ine before chrom atography. T he ins trum en ta tion  
for the  chrom atography consisted of a 610 Fluid un it pum p, a 
W IS P  710 B autoinjector, and a 470 scanning fluorescence 
detector, all from W aters Associates (E tten-L eur, T he N e th ­
erlands). All separations were perform ed on a N ova-Pak C18
column. Calculations were made on a NEC Pow erm ate SX  plus 
com puter using the Baseline 815 program  (W aters Associates).
/3E. T he RIA procedure was perform ed essentially as described 
by Sweep et al. (27), using an antiserum  kindly provided by Dr. 
V. M. W iegant, Rudolf M agnus Institu te  (U trecht, T he N e th ­
erlands).
Chemicals
All chemicals used were of analytical grade.
Statistical analysis
All data are presented  as the m ean ±  S E  of five to seven rats. 
Com parisons between IL-1 and  saline groups were made by 
analysis of variance with repeated m easurem ents to analyze 
the effects of the trea tm en t course. To get a fair picture of the 
effect of continuous IL-1 trea tm en t, analysis of repeated m eas­
ures was perform ed from days 2-7, as on the  first day changes 
occurred in ACTH, B, and  catecholam ine levels in plasma, and 
in body tem perature, food consum ption, and body weight, which 
in m ost instances surpass the changes seen from days 2-7. 
W hen analysis of variance revealed a statistically  significant 
difference, com parison of the  individual groups a t specific tim e 
points was further evaluated by S tu d en t’s t test, as were the 
effects of IL-1 on the  first day of trea tm en t. For single com ­
parisons between IL-1 and  saline groups, S tu d en t’s t te s t was 
used.
Results
Infusion of IL-lfi at a dose of 4.0 jug/day induced clear 
signs of physical discomfort to the animals, including 
piloerection and decreased physical activity, starting a 
few hours after implantation of the pumps. This visually 
observed uneasiness gradually diminished during the 
first day of the treatment period and had disappeared at 
the end of day 1. Infusion with a dose of 2.0 fig IL-l/day 
also induced signs of discomfort, which were less pro­
nounced than those induced by the 4.0-^g IL-1 dose. 
Treatment of rats with 0.5 fig IL-l/day or physiological 
saline did not perceptibly distress the animals.
Effects of IL-1 on plasma ACTH and B and on pituitary 
ACTH content and adrenal weight
Using osmotic minipumps, rats were continuously in­
fused for 7 days with 0.5, 2.0, or 4.0 fig IL-l/day or with 
physiological saline, and plasma levels of ACTH and B 
were monitored for 8 days, starting on the morning before 
implantation of the pumps. Plasma ACTH and B values 
in animals implanted with saline-filled osmotic pumps 
varied between 15-51 pg/ml and 24-50 nmol/liter, re­
spectively. Under the present conditions, the operation 
and infusion procedures, as such, virtually did not alter 
plasma ACTH and B levels, as demonstrated by the 
stable hormone levels in saline-treated rats.
Administration of 0.5 fig IL-l/day did not affect 
plasma ACTH and B levels (Fig. 1). Infusion of 2.0 fig
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F ig . 1. Effects of continuous infusion 
for 1 week of different doses of IL-1 (0.5, 
2.0, and 4.0 /¿g IL-l/day; • )  or physio­
logical saline (O) in rats on the concen­
trations of ACTH (left panels) and B 
(right panels) in plasma. Osmotic mini­
pumps were implanted between 1400- 
1600 h on day 0 {arrow). Data are ex­
pressed as the mean ± SE of five to seven 
rats. Asterisks mark statistically signifi­
cant differences between IL-1- and sa- 
line-treated rats. *, P < 0.05; **, P < 
0.005; ***, P <  0.0005 (by Student’s t 
test).
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IL-l/day induced a significant increase in plasma ACTH 
and B levels compared to those in saline-treated controls. 
Repeated measures analysis revealed a significant treat­
ment effect on plasma ACTH (days 2-7; P  <  0.0005) and 
B (days 2-7; P  <  0.05) in IL-l-infused rats compared to 
saline-treated controls. The maximal effect [ACTH, 
+184 ± 38% (P  <  0.005); B, +2114 ± 381% (P <  0.0005)] 
was observed on day 1 of treatment. Plasma levels had 
declined on day 2, but sustained elevations of ACTH and 
B levels were found up to day 6. Post-hoc analysis of 
individual groups by means of Student’s t test showed a 
significant increase in plasma levels of ACTH on days 1,
3, 4, 5, and 6 and of B on days 1 and 6 compared to 
saline-treated control values. When IL-1 was infused at 
a rate of 4.0 fig/day, a more pronounced effect on plasma 
ACTH (repeated measures analysis from days 2-7; P  <
0.0005) and B (days 2-7; P  <  0.005) levels was observed. 
Peak levels on day 1 were about 6.2 (ACTH; P  <  0.0005) 
and 17.5 (B; P  <  0.0005) times higher than those in 
saline-treated rats. Significant elevations of plasma 
ACTH levels were found from day 1 up to day 7, and
significant elevations of B occurred on days 1, 2, 4, and 
5.
The effects of continuous treatment of rats with IL-1 
on the ACTH content of the anterior pituitary {2.0-fig 
IL-1 experiment) and the weight of the adrenal glands 
(0.5-, 2.0-, and 4.0-^g IL-l/day experiments) were also 
studied. The ALs of rats treated for 1 week with 2.0 fig 
IL-l/day contained significantly more immunoreactive 
ACTH than those of saline-treated rats (IL-1 us. saline, 
436 ± 45 us. 291 ± 30 ng; P  <  0.05). Chronic administra­
tion of 2.0 and 4.0 fig IL-1 induced significant increases 
in total adrenal weight [summated weight of both adre­
nals of each rat, 2.0 fig IL-1 us. saline, 46.6 ± 1.4 us. 40.1 
± 1.6 mg (P <  0.05); 4.0 fig IL-1 us. saline, 48.7 ± 1.9 us.
44.0 ± 0.6 mg (P <  0.05)]. IL-1 at a dose of 0.5 fig/day 
failed to affect adrenal weight.
Effects of IL-1 treatment on in uitro f3E-IR and B 
release (Fig. 2)
After decapitation and dissection, ALs and adrenals 
were transferred to a superfusion apparatus, and the
2.0  Mg IL 1
1000
2.0  Mg IL 1
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effects of chronic treatment of rats with IL-1 on the in 
vitro release of 0E-IR and B, respectively, were studied. 
/3E-IR release was taken as an index for the secretory 
activity of pituitary corticotrophs. Figure 2 shows the 
pattern of spontaneous and CRF/ACTH-induced release 
of /3E-IR and B. The rate of release into the medium 
generally ranged from 350-1500 pg /3E-IR/AL-15 min 
and 35-120 ng B/2 adrenals -15 min. Superfusion of ALs 
for 30 min with medium containing CRF (10-9 m ) and of 
adrenals for 60 min with 250 pg/ml ACTH induced a 
rapid sustained increase in the amounts of /3E-IR and B 
found in the superfusates. The effects of CRF and ACTH 
on /3E-IR and B release, respectively, are expressed for 
each superfusion cell as a percentage of the computed 
basal release and listed in Table 1. Chronic treatment of 
rats with 4.0 fig IL-l/day significantly increased the 
spontaneous rates of secretion of 0E-IR (P <  0.05) and 
B (P < 0.05), which were determined from the concen-
0E-IR and the ACTH-induced B release from tissue of 
IL-1 (4.0 fig/day)-treated rats were significantly de­
pressed (both P  <  0.05) compared to the responses of 
these tissues in saline rats. Treatment with 2.0 and 0.5 
fig IL-l/day did not affect the basal secretory rate of the 
anterior pituitary or the adrenal gland, whereas a tend­
ency to a reduced response of the pituitary and adrenal 
glands to CRF and ACTH, respectively, was observed 
(Fig. 2). However, these differences did not reach statis­
tical significance (Table 1).
Plasma PRL and catecholamine levels
To examine whether IL-l-induced ACTH and B re­
lease in vivo is due to a stress effect of the IL infusion, 
plasma PRL and catecholamine concentrations, well 
known parameters for stress effects, were determined 
during continuous IL-1 administration. Basal plasma 
PRL levels in saline- and IL-l-treated rats varied be-
trations of these hormones in the first 11 superfusion tween 1140-2460 pg/ml. Chronic infusion with IL-1 did
fractions collected compared to treatment with saline 
(Fig. 2 and Table 1). On the other hand, the CRF-induced
not significantly affect PRL levels (data not shown). Due 
to sample shortage, plasma E and NE could only be
0.5  y .g IL 1 0 .5  U.Q IL 1
F ig . 2. Release of 0E-IR from rat ALs 
(left panels) of pituitaries or of B from 
adrenal glands (right panels) superfused 
in vitro. ALs and adrenals from rats 
chronically treated with IL-1 (•)  or sa­
line (O) in vivo were superfused for 165 
min with medium (fractions 1-11). Sub­
sequently, the ALs were superfused for 
30 min (fractions 12-13) with medium 
containing CRF (10-9 M), and the adre­
nals for 60 min (fractions 12-15) with 
medium containing 250 pg/ml ACTH. 
Thereafter, superfusion was continued 
with initial medium. Each value repre­
sents the mean ± SE of six rats. *, Sta­
tistically significant difference from con­
trol (P <  0.05, by Student’s t test).
c
e
in
_j<
triLUc
cn
c
c
E
in
v .
<
ocIHIo
cn
c
c
E
m
_ j<
—
(Ii
UJ
CD
?
0 2
12
10
8
6
4
2
6  8  10 12 14 16 18 2 0  22  
f r a c t io n  n u m b e r
2 .0  /xg IL 1
f r a c t io n  n u m b e r
c
E
in
in
r o
cd)■Ò
r o
C\J
OQ
o>
c
c
E
in
0)
03
cd)
u
• O
03
CvJ
CD
cn
c
O 2 4 6  8  10 12 14 16 18 2 0  2 2
f r a c t io n  n u m b e r
2 .0  Mg IL 1
0 2 6  8  10 12 14 16 18 2 0  2 2  
f r a c t io n  n u m b e r
6 0 0
5 0 0
4 0 0
3 0 0
200
100
4 .0  u g  IL 1
O 2 4 6  8  10 12 14 16 18 2 0  22
f r a c t io n  n u m b e r
0
4 .0  yu,g IL 1 
7 0 0  --------------------------------------------
O
O 2 4 6 8  10 12 14 16 18 2 0  22
f r a c t io n  n u m b e r
CHRONIC IL-1 INFUSION AND THE HPA AXIS 1159
T a b l e  1. Effects of in uiuo treatment of rats with IL-1 or saline on 
basal and CRF/ACTH-induced /3E-IR and B release in vitro
Spontaneous release0 Stimulation of release
(%)b
0E-IR (ng) B (ng) 0E-IR B
Saline 8.49 ± 1.56 757 ± 133 443 ± 69 401 ± 49
IL1 (0.5 fig) 9.69 ± 3.26 536 ± 92 425 ± 80 362 ± 35
Saline 10.59 ± 1.46 745 ± 64 463 ± 54 553 ± 75
IL1 (2.0 fig) 13.43 ± 1.64 647 ± 78 302 ± 55 434 ± 57
Saline 7.25 ± 0.80 584 ± 29 840 ± 166 485 ± 117
ILl (4.0 fig) 27.78 ± 6.24c 951 ± 126c 324 ± 73c 186 ± 15c
“Total content of /3E-IR and B in the first 11 superfusion fractions 
collected.
b Stimulation of /3E-IR/B release induced by CRF and ACTH, re­
spectively, is expressed as a percentage of calculated basal release, as 
described in the text.
c P <  0.05 vs. control.
measured in the 2.0- and 4.0-fig IL-l/day experiments, 
with the exception of basal levels in the latter (Table 2). 
One day after the start of the 2.0-fig IL-l/day infusion, 
plasma E and NE levels were significantly higher than 
those in the saline animals (P < 0.0005 and P  < 0.05, 
respectively). In the 4.0-fig experiment only NE levels 
were significantly higher on day 1 (P <  0.0005). The data 
in Table 2 allow us to conclude that chronic IL-1 infusion 
led to a short-lasting increase in circulating catecholam­
ine levels on the first day of treatment only.
Rectal temperature changes (Fig. 3)
Rectal temperature levels of rats on the morning of 
the day of implantation of the pumps (day 0) varied 
between 37.1-37.8 C and did not differ significantly 
between the treatment groups. In addition, saline-treated
rats maintained a virtually constant mean daily rectal 
temperature throughout the experimental period. Infu­
sion of IL-1 produced a brisk increase in rectal temper­
ature in rats (Fig. 3). Temperature peaked 1 day after 
implantation of pumps infusing IL-1 at rates of 0.5 and
2.0 Mg/day, and temperature had returned to the values 
found in saline-infused control rats on day 3. From then 
on, values in IL-1-treated rats were not different from 
those in the saline group. The mean maximal increase in 
temperature induced by the 2.0-fig IL-l/day dose (+1.7 
C) was significantly greater (P <  0.05) than that induced 
by the lower dose (+0.9 C). At a dose of 4.0 fig IL-l/day, 
rectal temperature also peaked on day 1 (+1.3 C) and 
then gradually declined but remained elevated through­
out the experimental period (analysis of variance, days
2-7, P  < 0.05). Post-hoc analysis of the individual groups 
in this experiment revealed that rectal temperatures were 
significantly elevated on days 1, 2, 3, 4, and 7.
Suppression of food intake and daily body weight change
(Fig. 4)
The effect of administration of IL-1 on food consump­
tion and daily body weight change was monitored for 9 
days and is shown in Fig. 4. There was a transient slight 
reduction in food consumption in saline-treated rats 1 
day after implantation of the osmotic pumps. This de­
crease is probably due to the anesthesia on the day of 
operation. Chronic treatment of rats with 0.5 fig IL-1/ 
day did not significantly affect daily food consumption. 
Analysis of repeated measures (days 2-7) revealed a 
depressive effect of the higher doses of IL-1 (2.0 fig IL-
1, P  < 0.05; 4.0 fig IL-1, P  < 0.0005) on food intake. One 
day after implantation of the pumps, the decrease in food 
intake was maximal [2.0 fig IL-1, —7.2 ± 1.6 g (us. saline, 
P  <  0.05); 4.0 fig IL-1, -8.2 ± 0.9 g (P < 0.0005)] and
T a b l e  2. Effects of chronic infusion of rats with IL-1 or saline on plasma E and NE concentrations (picograms per ml)
Day
0 1 2 3 4 5 6
E
Saline 34 ± 9 9 ± 2 17 ± 5 17 ± 1 20 ± 5 16 ± 1 28 ± 14
IL-1 2 fig 21 ± 7 62 ± 10b 34 ± 8 28 ± 7 20 ± 11 19 ± 3 19 ± 5
NE
Saline 182 ± 24 165 ± 36 202 ± 36 151 ± 13 106 ± 17 191 ± 70 244 ± 73
IL-1 2 fig 133 ± 12 323 ± 51“ 260 ± 52 97 ± 24 50 ± 23 121 ± 39 125 ± 55
E
Saline 31 ± 13 38 ± 9 20 ± 4 19 ± 4 32 ± 6 16 ± 4
IL-1 4 fig 51 ± 8 67 ± 2 7 19 ± 9 24 ± 6 28 ± 2 11 ± 3
NE
Saline 136 ± 25 134 ± 24 123 ± 18 88 ± 4 72 ± 18 49 ± 14
IL-1 4 fig 368 ±  176 201 ± 36 54 ± 12 97 ± 43 96 ±33 76 ± 36
Analysis of variance from days 2-6 revealed no statistically significant differences for either E or NE levels between rats infused with IL-1 or
saline (P >  0.10).
0 P < 0.05 vs. control (by Student’s t test). 
b P <  0.0005 vs. control (by Student’s t test).
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Fig . 3. Effects of chronic administration of IL-1 (0.5, 2.0, and 4.0 fig/ 
day; • )  on rectal temperature compared with values during saline 
infusion (O). Each point represents the mean ± SE of five to seven rats. 
By analysis of variance, days 2-7: 0.5 fig IL-l/day, P <  0.05; 2.0 fig IL- 
l/day, P > 0.10; 4.0 fig/day, P < 0.05. Statistically significant differ­
ences: *, P <  0.05; **, P <  0.005; ***, P <  0.0005 (by Student’s t test).
values remained significantly lower in these animals than 
in their saline-treated controls until day 3 (2.0 fig) and 
day 5 (4.0 fig), respectively.
There was only a small (0.5 fig IL-1, —3.4 ± 1.8 g; 2.0 
fig IL-1, —7.1 ± 1.9 g) or no (4.0 fig IL-1) decrease in 
body weight on the first day of saline infusion (Fig. 4). 
A statistically significant reduction in body weight gain
1 treatment did not notably affect the change in body 
weight of the animals compared to saline infusion. Con­
tinuous infusion of 2.0 and 4.0 fig IL-l/day produced a 
more distinct weight loss in rats. Weight loss was already 
maximal on the first day of infusion [(2.0 fig IL-l/day, 
—15.2 ± 1.3 g (vs. saline, P  <  0.0005); 4.0 fig IL-l/day, 
—11.8 ± 3.6 g {vs. saline, P  <  0.005)]. The daily body 
weight change of IL-1-treated rats reached approxi­
mately initial levels by the third day. Thereafter, the rate 
of body weight increase was virtually the same for both 
IL-1- and saline-treated groups of animals.
Chronic infusion of IL-1 at doses of 0.5, 2.0, and 4.0 
fig/day into rats had no effect on total daily fluid intake 
(data not shown).
Discussion
The present study demonstrates that continuous ip 
infusion of rats with rather low doses of IL-1 (2.0 and
4.0 fig/day) induces a dose-dependent and sustained in­
crease in plasma ACTH levels. IL-1 at a dose of 0.5 fig/ 
day was not active. Together with the increased ACTH 
content of the anterior pituitary, this effect reflects in 
vivo increased biosynthesis of ACTH induced by IL-1. 
IL-1, indeed, has been reported to increase ACTH bio­
synthesis in corticotroph cells, possibly at the transcrip­
tional stage (28-30). The changes in plasma ACTH levels 
are parallelled by those in B; the maximal effect of the 
IL-1 treatment occurs on day 1, and hormone levels 
remain on a less elevated plateau level from days 2-6. 
On day 7, plasma ACTH (2.0-fig experiment) or B (2.0- 
and 4.0-fig experiments) levels had returned to control 
values, whereas plasma ACTH in the 4.0-fig IL-1 exper­
iment was still elevated on this day. The increase in 
plasma B levels was parallelled by an enlargement of the 
adrenal glands (11-16%), which is a well known conse­
quence of chronic activation of the HPA axis.
There are two other in vivo studies on the effects of 
chronic treatment of rats with IL-1 on the activity of the 
HPA axis (31, 32). In those studies ACTH and glucocor­
ticoid levels were determined at the end of the treatment 
period in plasma of decapitated rats. In the present study 
the effects of continuous infusion of rats with IL-1 on 
ACTH and B levels in plasma, collected by means of a 
chronic jugular cannula, were monitored daily for 1 week. 
In our study, unlike in the above-mentioned studies, 
plasma PRL, E, and NE levels were followed together 
with body temperature and food intake to detect aspecific 
secondary stress effects. Gaillard et al (31) showed in a 
preliminary report that ACTH levels in plasma of rats 
chronically treated for 1 week with 5.0 fig IL-l/day and 
decapitated at the end of the infusion period had not
of animals infused with 0.5 fig IL-l/day was found on changed, whereas the mean adrenal weight and pituitary 
day 1 (—6.3 ± 1.6 g; vs. saline, P  <  0.05). Thereafter, IL- ACTH content were significantly increased in IL-1 rats.
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Fig . 4. The effect of continuous infusion 
of IL-1 (•)  or saline (O) for 7 days on 
food intake and daily body weight change 
of rats. The daily body weight change for 
each rat was calculated by subtraction of 
the daily measured body weights on sub­
sequent days. Statistically significant 
differences: *, P  <  0.05; **, P <  0.005; 
***, P <  0.0005 (by Student’s t test).
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Naito et al. (32), in a cross-sectional study, showed that 
repetitive administration of 1.0 fig IL-1 twice a day for 
periods up to 10 days induces an increase in the ACTH 
content of the anterior pituitary as early as day 3, 
whereas the wet weight of the adrenal glands had not 
increased significantly in rats until day 10 of the treat­
ment period. Plasma ACTH concentrations measured 2-
4 h after the last bolus injection were significantly higher 
after 1, 3, 7, and 10 days of treatment with IL-1 compared 
with those in saline-treated rats.
In our study chronic treatment of rats with 4.0 fig IL- 
l/day resulted in an increase in the spontaneous in vitro 
release of 0E from the anterior pituitary and of B from 
the adrenals, whereas no significant effects were ob­
served using lower doses of IL-1. As ACTH and /3E are 
generally secreted simultaneously (33), one may assume 
that the secretion of ACTH had also increased. Remark­
ably, 1 day before decapitation, plasma levels were only 
slightly, although significantly (ACTH), or not at all (B) 
elevated compared to values in saline control rats. Thus,
although a firm increase in the in vitro secretory activity 
of the pituitary and adrenal glands was observed, this 
was only paralleled by a small increase in plasma ACTH 
levels. One should bear in mind, however, that in vitro, 
these tissues are devoid of any humoral or neuronal 
regulatory input signal and, thus, might exhibit a secre­
tory pattern that is probably distinct from that in vivo. 
It is difficult to understand why the in vitro hormonal 
responses of the pituitary and adrenal glands of chroni­
cally IL-1-treated rats to CRF and ACTH, respectively, 
were diminished. A depletion of releasable ACTH stores 
in the pituitary by a higher spontaneous release of ACTH 
is not likely, as pituitary ACTH levels were significantly 
increased in IL-1 rats. Alternatively, it might be that 
long term activation of the HPA axis in vivo leads to 
desensitization of pituitary and adrenal tissues to secre- 
tagogues. Continuous intracerebroventricular infusion of 
CRF in rats for 52 days, however, has been reported to 
cause a persistent increase in plasma ACTH levels (34), 
indicating that a significant desensitization to the effect
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of CRF in the anterior pituitary did not occur. Likewise, 
Rebuffat et al. (35) recently showed that chronic treat­
ment of rats bearing adrenocortical autotransplants for
2 weeks with ACTH does not affect the in vitro respon­
siveness of these transplants to ACTH. Therefore, the 
possibility should be considered that the reduced sensi­
tivity of the pituitary and adrenal glands in vitro resulted 
from direct effects of IL-1 on these glands.
From our study it cannot be concluded whether the 
observed increase in plasma hormone levels resulted 
from direct effects of IL-1 on corticotroph and/or adre­
nocortical cells or via an action on the central nervous 
system. There is compelling evidence indicating that 
acute administration of IL-1 stimulates plasma ACTH 
and B levels, primarily through an action on the brain. 
This effect involves, directly or through catecholamine 
(36) or prostaglandin (10, 37) release, the secretion of 
CRF from neurosecretory cells in the hypothalamic par­
aventricular nucleus (6, 7, 9,12). Naito et al. (32) showed 
that chronic administration of IL-1 induces an increase 
in the levels of CRF in the hypothalamus, which suggests 
that during these conditions the brain is a site of neu­
roendocrine action of IL-1. It is still a matter of debate, 
however, whether IL-1 can act directly on corticotroph 
and adrenocortical cells to stimulate hormone release. 
Although IL-1 does not alter ACTH (6, 9, 29) or B (38, 
39) release from cultured anterior pituitary or adreno­
cortical cells during short term (<4-8 h) incubation, 
prolonged (>12 h) treatment of these cells with IL-1 is 
reported to induce a dose-dependent increase in ACTH 
(29, 30, 40, 41) and B (38, 39, 42) secretion. It cannot be 
excluded, therefore, that such a delayed action of IL-1 
contributes to enhanced ACTH and B levels during long 
term treatment in vivo. It may be that chronic IL-1 
treatment activates the HPA axis via two mechanisms 
of action: 1) a rapid indirect effect, which increases 
plasma ACTH and B through activation of the hypotha­
lamic CRF neurons, and 2) a delayed effect, which results 
from a direct stimulation of pituitary and/or adrenal 
cells.
Catecholamines released from the sympathetic adren- 
omedullary system upon stress may contribute to in­
creased plasma ACTH levels (43). Rivier et al. (8) showed 
that acute administration of IL-1 to rats induces a dose- 
related increase in plasma levels of ACTH, B, E, and 
NE. We determined plasma levels of NE and E during 
chronic infusion with IL-1. Two and 4.0 fig IL-l/day 
induced significant increases in plasma NE and/or E 
concentrations only on the first day of infusion, whereas 
a prolonged increase in plasma ACTH levels was found. 
Thus, although chronic IL-1 administration induces a 
transient increase in plasma catecholamine levels, acti­
vation of pituitary adrenergic receptors by circulating 
catecholamines is unlikely to be a mechanism by which
IL-1 stimulates sustained ACTH secretion. As peripheral 
administration of IL-1 has been shown to change the 
activity of central noradrenergic neurons (36, 44), and 
NE and E are secreted locally within the median emi­
nence in response to IL-1 (45), we cannot exclude that 
modulation of the central catecholaminergic system con­
tributes to the action of IL-1 on ACTH levels. As far as 
PRL is concerned, it has been demonstrated that acute 
administration of IL-1 to rats does not affect the plasma 
concentration of this hormone (7, 10, 46). In the present 
study we showed that chronic administration of IL-1 also 
does not affect plasma PRL concentrations.
Another activity of IL-1 is the capacity to elevate body 
temperature. The effects of IL-1 as an endogenous me­
diator of endotoxin-induced fever are well documented 
(13). In the present study we confirm that chronic ad­
ministration of IL-1 induces dose-dependent fever in 
rats. Although the 2.0-^g dose produced a significantly 
higher peak the first day of infusion than the 4.0-fig dose, 
the latter produced a rise in temperature that lasted 
longer, until the end of the experiment. It is clear from 
the present study and a number of acute studies using 
subpyrogenic doses of IL-1 (3), nonpyrogenic IL-1 ana­
logs (47), and injections of IL-1 in the preoptic area (48) 
that stimulation of ACTH secretion after IL-1 adminis­
tration does not simply depend on fever production.
The demonstration that IL-1 suppresses food intake 
and body weight gain is in good agreement with previous 
reports (14, 49-51). No effects of IL-1 were found on 
water intake, indicating that the observed weight loss is 
not simply caused by altered fluid intake. The effect of 
IL-1 on body weight change was maintained during the 
first 2 days of infusion and had been lost on day 3 of 
treatment. An elegant study by Mrosovsky et al. (22) 
clearly demonstrated that recovery of body weight and 
food intake is not due to failure of the osmotic pumps or 
hindrance of the release of IL-1 into the peritoneal 
cavity, and that osmotic pumps are effectively delivering 
bioactive IL-1 for at least 1 week. These researchers 
suggested that tolerance to the anorectic effect of IL-1 
develops within a few days.
It is not clear whether the anorectic effects of IL-1 are 
mediated through effects on the brain. Intracerebroven- 
tricular injections of IL-1 do not affect food intake (15), 
supporting a peripheral site of action. However, IL-1 
specifically suppresses electrical activity of glucose-sen­
sitive neurons in the hypothalamus (16), and intracere- 
broventricular injection of anti-CRF antiserum before ip 
IL-1 administration reduces feeding suppression (51). 
This suggests that CRF secretion should at least partially 
be involved in the effect of IL-1 on food intake.
We have shown that continuous ip infusion of rats 
with IL-1 induces a dose-dependent and sustained acti­
vation of the pituitary-adrenal axis. On only the first day
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of infusion with 2.0 and 4.0 fig IL-1 were rats ill and 
plasma catecholamine levels elevated. Daily body weight 
gain was temporarily reduced, but had returned to con­
trol values on day 3. Therefore, it is not likely that the 
effects on the HPA axis can be solely explained by the 
illness-inducing effects of IL-1, as these effects were only 
observed during the first days, whereas plasma ACTH 
and B levels were elevated throughout the treatment 
period. It is also not likely that activation of the HPA 
axis is simply secondary to changes in body temperature, 
as in the 2.0-fig IL-1 experiment temperature was only 
elevated during the first 2 days of treatment, whereas 
plasma ACTH and B levels were persistently increased.
Acute infection and inflammation are accompanied by 
a sustained activation of the HPA axis, an increase in 
body temperature, and a decrease in food intake. It is 
assumed that IL-1 is, directly or indirectly, an important 
mediator of these changes. Our study shows that contin­
uous administration of IL-1 to rats elicits enhanced 
activity of the HPA axis and that it is unlikely that this 
stimulation can be simply explained by stress effects 
induced by IL-1 treatment.
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